Widespread acceptance of COVID-19 vaccines is crucial for achieving sufficient
immunization coverage to end the global pandemic, yet few studies have investigated …

Background As mass vaccination campaigns against coronavirus disease 2019 (Covid-19)
commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes …

Background: COVID-19 vaccines have had expedited reviews without sufficient safety data.
We wanted to compare risks and benefits. Method: We calculated the number needed to …

We report that in a cohort of 45,965 adults, who were receiving either the ChAdOx1 or the
BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2 …

Anti-viral immunity continuously declines over time after SARS-CoV-2 infection. Here, we
characterize the dynamics of anti-viral immunity during long-term follow-up and after …

The current surgein infections with the SARS-CoV-2 Delta variant has made it clear to health
care workers and the public alike that fully vaccinated people remain at risk for SARS-CoV-2 …

Six months of COVID vaccines: what 1.7 billion doses have taught scientists. - Abstract -
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …

On July 8, 2021, Pfizer and BioNTech announced they would be seeking US and European
authorization for administration of a third booster dose of their COVID-19 vaccine. 1 The …

Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in
England starting on 14 September 2021. We used a test-negative case–control design to …

There is a public health need to understand how different frequencies of COVID-19 booster
vaccines may mitigate the risk of severe COVID-19, while accounting for waning of …